TFF Pharmaceuticals’ (TFFP) Thin Film Freezing Technology Demonstrates Superior Pulmonary Drug Delivery

TFF Pharmaceuticals (Nasdaq: TFFP) leads the PRISM Emerging Pharmaceuticals Index with its shares trading up 7% after announcing promising preclinical data published in the “Journal of Drug Delivery Science and Technology.” The company is focused on transforming medicines into stable dry powders, offering alternatives to traditional injection methods. With its proprietary Thin Film Freezing (TFF) platform, TFF Pharmaceuticals is advancing its pipeline across multiple therapeutic areas, including intranasal, inhalation, intraocular and topical delivery.

The company’s initial pipeline focus targets lung-directed drugs, leveraging its extensive expertise in respiratory medicine delivery. The newly published study validates TFF technology’s potential to improve pulmonary drug delivery, highlighting its advantages over jet-milling and spray-drying methods for producing superior inhalational dry powder formulations.

Dr. Harlan Weisman, TFF Pharmaceuticals CEO, stated, “It is gratifying to have the continued support of the scientific community for our approach and to have ongoing validation of our science. The more rapid and uniform distribution of TFF-generated dry powders in the lung with a lower airway-to-lung deposition ratio differentiates our inhalational products from products generated by other technologies and provides the opportunity to increase efficacy and lower risk of toxicities.”

Highlights:

• Enhanced Drug Distribution:
  • TFF-processed inhalational dry powders showed the most homogeneous distribution in lung tissue compared to jet-milled and spray-dried powders.
  • Lower airway-to-lung deposition ratio (1.27) for TFF powders compared to spray-dried (1.76) and jet-milled (2.73) formulations.
• Rapid Particle Disaggregation:
  • The TFF powder’s nanoaggregates rapidly disaggregate, leading to smaller particle sizes and improved movement within the lungs.
• Potential to Improve Treatment:
  • TFF inhalational dry powders may enhance treatment efficiency and reduce toxicity for lung diseases, highlighting the potential for pulmonary drug delivery.

Earlier this month, TFF Pharmaceuticals announced a partnership with Emory University and BARDA to develop a dry powder inhaled mRNA-based treatment for influenza and COVID-19.